Eli Lilly upgraded to buy at Mizuho on positive donanemab data



Eli Lilly upgraded to buy at Mizuho on positive donanemab data



READ SOURCE

READ  Route Mobile: What should investors do after the 105% stellar listing gain?

LEAVE A REPLY

Please enter your comment!
Please enter your name here